Citi Pharma Limited (PSX:CPHL)
87.65
+5.49 (6.68%)
At close: Apr 17, 2026
Citi Pharma Revenue
Citi Pharma had revenue of 4.33B PKR in the quarter ending December 31, 2025, with 22.58% growth. This brings the company's revenue in the last twelve months to 14.10B, up 6.86% year-over-year. In the fiscal year ending June 30, 2025, Citi Pharma had annual revenue of 13.15B with 6.00% growth.
Revenue (ttm)
14.10B
Revenue Growth
+6.86%
P/S Ratio
1.42
Revenue / Employee
26.55M
Employees
531
Market Cap
20.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 13.15B | 744.28M | 6.00% |
| Jun 30, 2024 | 12.41B | 12.26M | 0.10% |
| Jun 30, 2023 | 12.40B | 2.62B | 26.76% |
| Jun 30, 2022 | 9.78B | 3.98B | 68.75% |
| Jun 30, 2021 | 5.80B | 2.27B | 64.29% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Abbott Laboratories (Pakistan) | 75.40B |
| GlaxoSmithKline Pakistan | 65.90B |
| The Searle Company | 33.26B |
| AGP Limited | 28.89B |
| Highnoon Laboratories | 27.71B |
| Ferozsons Laboratories | 22.22B |
| Macter International | 11.58B |
| Otsuka Pakistan | 4.26B |